Search

Author/Creator Atalay, Selma

1. Regaining adequate treatment responses in patients with psoriasis who discontinued dose reduction of adalimumab, etanercept or ustekinumab. (1st December 2022)

Authors:
van der Schoot, Lara S.; Atalay, Selma; Otero, Marisol E.; Kievit, Wietske; van den Reek, Juul M.P.A.; de Jong, Elke M.G.J.
Journal:
British journal of dermatology
Issue:
Volume 187:Number 6(2022)
Page Start:
1028
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Regaining adequate treatment responses in patients with psoriasis who discontinued dose reduction of adalimumab, etanercept or ustekinumab. (20th August 2022)

Authors:
van der Schoot, Lara S.; Atalay, Selma; Otero, Marisol E.; Kievit, Wietske; van den Reek, Juul M.P.A.; de Jong, Elke M.G.J.
Journal:
British journal of dermatology
Issue:
Volume 187:Number 6(2022)
Page Start:
1028
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Serum drug levels and anti-drug antibodies in the context of dose tapering by interval prolongation of adalimumab, etanercept and ustekinumab in psoriasis patients: results of the CONDOR trial. (4th July 2022)

Authors:
Atalay, Selma; Berends, Sophie E.; Groenewoud, Hans M. M.; Mathot, Ron A. A.; Njoo, David M.; Mommers, Johannes M.; Ossenkoppele, Paul M.; Koetsier, Marjolein I. A.; Berends, Maartje A.; de Vries, Annick; van de Kerkhof, Peter C. M.; den Broeder, Alfons A.; de Jong, Elke M. G. J.; van den Reek, J...
Journal:
Journal of dermatological treatment
Issue:
Volume 33:Number 5(2022)
Page Start:
2680
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗